Clinical Trial Update: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing brolucizumab vs. aflibercept for wet macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Brolucizumab (brolucizumab)

Snippet

Sponsor: Faculty Hospital Kralovske Vinohrady | Conditions: Wet Macular Degeneration | Phase 4 | Status: WITHDRAWN